Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Washington Univ. School of Medicine S1PR5 compound [18F]7a
- Development stage
- Unknown
- Lead developer
- Washington University School of Medicine
- Modality
- Positron Emitters → Radiopharmaceuticals
01
Overview
Washington Univ. School of Medicine S1PR5 compound [18F]7a: sourced facts only. name: "[18F]7a had Kd values of 2.2, 4.6, and 27.6 nM for recombinant human S1PR5 cell membranes, C57BL/6 mouse brain, and human cerebral cortex, respectively." [PMID:40476381]; target: "[18F]7a had Kd values of 2.2, 4.6, and 27.6 nM for recombinant human S1PR5 cell membranes, C57BL/6 mouse brain, and human cerebral cortex, respectively." [PMID:40476381]; developer: "Department of Radiology, Washington University School of Medicine, St. Louis, Missouri 63110, United States." [PMID:40476381]
02
Targets
S1PR5 (Sphingosine-1-phosphate receptor 5)
Beyond the preview
Go deeper on Washington Univ. School of Medicine S1PR5 compound [18F]7a.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Washington Univ. School of Medicine S1PR5 compound [18F]7a.